Japan's aesthetic medicine market has expanded consistently since the pandemic. The 2024 market (measured by facility revenue) reached ¥631 billion, up 106.2% year on year. Lower psychological barriers among women, growing demand from men in their 20s and 30s, inbound demand, and continued growth in the number of facilities are cited as drivers.
Reading only that number, however, misleads about operating reality.
1. Macro environment — revenue grows, profit does not stay
An analysis aggregating 248 corporate entities nationwide found combined revenue rising from ¥211.97 billion in 2022 to ¥313.76 billion in 2024 — roughly 1.5×, with the most recent year up 29.9%.
Profit, however, reached only ¥8.27 billion (up 22.6%), leaving a margin of about 2.6%. Heavy advertising costs inherent to a BtoC market, rising medical material costs, import cost increases from a weak yen, and wage inflation all bite simultaneously, producing a structure where revenue grows but profit does not stay.
The market has also clearly polarized. Operators under ¥500 million in revenue account for 73.7% of the total, most of them thin-margin and exposed to price competition. In 2024, three closures and dissolutions plus four bankruptcies — seven in total — marked the highest count in a decade. The analysis reads this as attrition beginning among single-menu clinics unable to keep pace with trends and diversifying customer needs.
Expansion and attrition occurring simultaneously — bankruptcies rising even as the overall market grows — is the defining characteristic of cosmetic surgery in 2026.
Regulation moved significantly
Under the amended Medical Care Act promulgated on December 12, 2025, institutions providing aesthetic treatment must report their safety assurance policies, organizational structures, and accident prevention measures to the prefectural governor, with the contents published by the prefecture (false or omitted reports draw correction orders).
The amendment also formally positioned online consultation in law and, as part of physician maldistribution measures, introduced advance notification and regional healthcare consultation requirements for opening in areas with excess outpatient physicians.
2. Characteristics of newly opened clinics — easy to open, hard to survive
The environment for new openings has tilted sharply over two years.
One driver is the surge in what is called "chokubi" — young physicians moving directly into self-pay aesthetic medicine after their two-year initial clinical training, with almost no insured practice experience. Market expansion combined with quality-of-life preferences has concentrated physicians in urban aesthetic clinics.
In response, MHLW is advancing a physician maldistribution package: effectively requiring insured practice experience, tightening clinic manager requirements, and restricting openings in areas with excess outpatient physicians. A proposal requiring a defined number of years of insured practice experience before providing insured care after opening (targeted for FY2027) is also under consideration, and the final design — including its applicability to self-pay-only clinics — remains fluid.
Under this tightening, the character of new clinics is changing.
First, more specialized and brand-led openings. Rather than competing head-on with major chains, clinics narrow by region, concern, or gender — AGA and men's aesthetics, body contouring, eye-area specialization, regenerative and anti-ageing medicine — building expertise and brand value in a single domain.
Second, harder physician recruitment. Wage inflation is slowing branch expansion, and securing branch director candidates is becoming the bottleneck.
Third, structural readiness as a precondition. Advertising guideline compliance and safety management systems must now be designed in from opening, marking the transition from "open and they will come" to "chosen for trustworthiness and operational discipline."
On economics, initial investment (interior, lasers and HIFU devices, advertising) is heavy while acquisition costs stay elevated as search and social ad prices rise. Cash flow designs dependent on prepayments and large contracts are inseparable from the consumer complaint and refund delay risks discussed below.
3. Revenue areas — the surgical and non-surgical portfolio
Revenue divides broadly into surgical procedures and non-surgical work (minimally invasive treatments, injectables, device-based treatments, skin care, hair removal).
Surgical procedures — full incision double eyelid surgery, liposuction, breast augmentation — carry high prices and high gross margins with large per-case value, but demand surgeon skill, safety management, and post-operative follow-up, and sit at the center of adverse event and dispute risk. The amended Medical Care Act and MHLW notifications point toward clarifying that highly invasive procedures such as liposuction may be performed only by physicians, and toward defining operator requirements.
By contrast, recent growth is driven by non-surgical work. HIFU and cryolipolysis for non-invasive contouring and lifting, hyaluronic acid and botulinum toxin injectables, laser and light treatment for pigmentation and skin quality, and medical hair removal have broadened the base on short downtime and relatively low prices. Per-case value is lower, but repeat rates are high and these serve as entry products that upsell into surgical work.
Portfolio design combining non-surgical menus as the acquisition channel with surgical and injectable menus as the revenue source separates strong operators from weak ones.
Growth areas and their risks
A third pillar lifting the market is men's aesthetics and regenerative medicine. Growing demand among men in their 20s and 30s, and the rise of AGA and men's aesthetics specialty clinics, are cited as continuing drivers.
In regenerative and anti-ageing medicine, exosome therapy spread rapidly. An international report by a Kyoto University group found 669 domestic facilities offering exosome therapy as of 2023, with roughly 73% (488 facilities) describing it online as "regenerative medicine." Safety data remain insufficient and adverse events have been reported, and MHLW is considering regulatory measures including revising the Act on Securing Safety of Regenerative Medicine.
The more profitable a new area looks, the more likely regulation can change what may be offered or claimed overnight — making revenue dependent on a single new procedure a high-risk design.
Acquisition and advertising regulation
Multi-channel operation combining SEO, map optimization, social media, YouTube, beauty portals, and review sites has standardized. Instagram, TikTok, and influencer experience posts have strong appeal to women in their 20s and 30s.
Under the medical advertising guidelines, however, patient testimonials and reviews, before-and-after images lacking detailed explanation, exaggerated claims such as "guaranteed improvement," superlatives such as "best in Japan," and price-forward messaging such as "half price campaign" are prohibited in principle. Case photos require meeting conditional release requirements — treatment content, cost, risks, and side effects stated together.
With advertising differentiation narrowed by regulation, differentiation on substance — track record, counseling quality, specialization — carries more weight.
4. Self-pay services — a world without official pricing
Nearly every menu item in cosmetic surgery is self-pay, and no official pricing exists. Clinics set prices freely, producing two structural problems: price competition and price opacity.
The ranges below are indicative, based on published clinic pricing and comparison articles; actual costs vary substantially by technique, extent, anesthesia, options, and monitor terms.
| Area | Procedure | Typical range | Note |
|---|---|---|---|
| Surgical (eyes) | Double eyelid, suture method | ~¥30,000–300,000 | Point suture ~¥50,000–150,000; line suture ~¥150,000–300,000 |
| Surgical (eyes) | Double eyelid, incision method | ~¥200,000–400,000 | With epicanthoplasty ~¥400,000–700,000 |
| Surgical (body) | Breast augmentation (implant) | ~¥700,000–2,000,000 | The archetypal high-price, high-margin item |
| Surgical (body) | Breast augmentation (fat grafting) | Surgery alone ~¥300,000–700,000; with liposuction ~¥500,000–1,500,000 | Value stacks when paired with liposuction |
| Injectable | Hyaluronic acid augmentation | ~¥100,000–1,000,000 per session | Multiple sessions assumed |
| Non-surgical device | HIFU, laser, skin treatments | From tens of thousands per session | High repeat rate; functions as entry product |
| Non-surgical | Medical hair removal (full body) | Tens of thousands to hundreds of thousands | Price competition is fierce as an acquisition hook |
Management issues specific to self-pay
First, price competition and average transaction value. Major chains present entry products such as suture double eyelids and hair removal at low or monitor pricing, then upsell in counseling to high-value surgical, augmentation, and injectable work. With over 70% of operators under ¥500 million in revenue, the dilemma of thin margins if you cut prices and lost patients if you don't is a contributing cause of rising bankruptcies.
Second, medical loans and large contracts. Double eyelid surgery and augmentation carry large totals, and installment payment through medical loans is widespread. This raises average transaction value while also breeding cancellation and refund disputes.
Third, contracts, counseling, and consumer complaints. In the National Consumer Affairs Center's PIO-NET data, complaints about aesthetic medical services rose sharply: 3,798 in 2022, 6,281 in 2023, and 10,717 in 2024. Disputes over cancellation fees for same-day procedures after contracting, and sales approaches that create anxiety or push immediate decisions on discounted monitor contracts, have surfaced repeatedly.
MHLW's report on appropriate provision of aesthetic medicine (November 22, 2024) identified structural problems including cases where physicians simply performed treatments the patient decided in consultation with a counselor alone, and unclear criteria for violations of the Medical Practitioners Act and the scope of on-site inspections. The resulting amended Act and notifications mandate pre-procedure explanation of risks and complications, costs, post-operative follow-up, and safety management; deter procedures by unqualified staff or nurses alone; and strengthen enforcement against exaggerated and misleading advertising including social media and influencer content.
Fourth, trustworthiness in self-pay care. Price wars, opaque pricing, aggressive sales, and adverse event coverage damage trust across the industry, raising both acquisition costs and reputational risk. Conversely, clear pricing, counseling quality, post-operative follow-up, and visible safety management become differentiators and acquisition assets in a tightening regulatory phase. Being self-pay means freedom in pricing and, equally, self-imposed discipline in pricing and accountability — that is where 2026 has landed.
5. Management implications
The market keeps expanding, but that expansion is led by large and listed groups, and attrition has begun among thin-margin small and single-menu operators. The survival strategy for smaller clinics comes down to avoiding head-on price competition and securing average transaction value and repeat business through specialization and brand — by region, concern, gender, or domain.
Men's aesthetics and regenerative medicine are attractive growth areas, but as exosomes illustrate, regulation can change what may be offered overnight. Avoid dependence on a single new procedure and smooth revenue through a portfolio: non-surgical (entry) × surgical and injectable (revenue) × skin and hair removal (repeat).
Regulation is becoming the arena for differentiation rather than a cost. Safety management reporting under the amended Act, advertising guidelines, and proper counseling and contracting will push out operators that cannot comply — while becoming an intangible trust asset for clinics that systematize clear pricing, accountability, post-operative follow-up, and compliant case photography early.
With physician recruitment structurally harder (chokubi restrictions, manager requirements, opening regulations), recruiting capability, retention, and developing branch director candidates become the constraints on branch expansion and scale.
Finally, the surge in consumer complaints (over 10,000 in 2024) is a shared reputational risk. Cash flow designs dependent on prepayments and large loans, and sales approaches pushing same-day contracts, trade short-term revenue for refund delays, public backlash, and administrative guidance. Sustainable operation is shifting its center of gravity from acquisition power to trustworthiness and operational discipline.
6. How an AI EMR addresses these problems — feature by feature
In cosmetic surgery, the explanation and safety records the amended Medical Care Act requires are themselves your risk management. Since what is tested is not whether you explained but whether the explanation is on record, the EMR occupies a different position here than in other specialties. Here is how Pottech's AI Karte answers that, feature by feature.
Feature 1: Audit and compliance — discharge accountability through records
All CRUD operations and access events are logged, with passkey-capable authentication and complete multi-tenant isolation, aligned to Japan's three-ministry, two-guideline framework.
The amended Medical Care Act imposes an obligation to report safety assurance policies, structures, and accident prevention measures to the prefectural governor. Simultaneously, explanation of pre-procedure risks and complications, costs, post-operative follow-up, and safety management became mandatory. What is tested is not whether you explained but whether the explanation is on record.
Behind the surge past 10,000 consumer complaints in 2024 lies the gap between what was explained at contracting and what patients understood. Being able to trace who explained what, when, and what the patient consented to is a direct dispute-prevention mechanism. For groups operating multiple sites, tenant isolation and access boundary control are also prerequisites.
Feature 2: Document generation — standardize consent and explanation documents
AI generates medical documents from patient data, with registered templates preserving the clinic's format and a physician review and correction flow built in.
Cosmetic surgery consent forms must state risks, complications, downtime, costs, and post-operative follow-up for each procedure. The more menu items, the more document variants, and the greater the risk of stale content and missing sections. Centrally managing templates so that required items emerge automatically in step with the selected procedure is compliance with the explanation mandate itself.
Because accountability and advertising regulation are especially strict in aesthetic self-pay care, governance ensuring AI-generated explanatory text does not breach guidelines is a precondition. Physician review of generated content is mandatory.
Feature 3: Charting and orders — connect counseling through to procedure records
AI structures consultation audio directly into the chart, and web questionnaires are digitized automatically.
MHLW's review committee report identified as a structural problem cases where physicians simply performed treatments the patient decided with a counselor alone. The answer to that criticism is having the physician's examination and judgment on record. Recording the full chain — counseling, physician examination, consent, procedure record, post-operative follow-up — satisfies both reporting obligations and dispute prevention.
Feature 4: Practice analytics — see profitability inside a thin-margin structure
Visit volume, revenue per patient, monthly trends, and patient attributes are aggregated and visualized automatically, with CSV export.
With an industry average margin around 2.6%, operating without visibility into profitability by menu item and advertising channel is dangerous. Given that entry products (hair removal, skin) run thin for acquisition purposes while revenue sources (surgical, injectable) carry high prices, blended revenue obscures reality. The conversion rate from entry product to revenue menu is this business model's lifeline, and whether you can follow it numerically determines decision quality.
With search and social ad prices rising and acquisition costs stubbornly high, measuring return by channel is also essential.
Feature 5: Booking and reception — manage prepayments and procedure schedules
In-person and online bookings are managed together, searchable instantly by name, phone number, or card number.
In an industry where multi-session course contracts are standard, tracking contracted versus delivered sessions connects directly to accounting. Because cash flow designs dependent on prepayments and large loans carry refund delay risk, accurate visibility into consumption is management control itself. And since cancellation fee disputes sit at the center of consumer complaints, retaining a history of booking changes and cancellations is also a line of defense.
Feature 6: Patient PHR app integration ("Pote-kun") — systematize post-operative follow-up
Fee notifications and digital receipts, appointment booking, and LINE login with push notifications.
Now that the amended Act mandates explanation of post-operative follow-up, follow-up has moved from good practice to obligation. Delivering progress checks, next-procedure guidance, and downtime instructions to patients satisfies the obligation while raising repeat rates. Digital receipts also respond directly to the industry's price transparency problem.
Primary sources
- Yano Research Institute, "Survey of the aesthetic medicine market (2025)" https://www.yano.co.jp/press-release/show/press_id/3844
- Tokyo Shoko Research, "The aesthetic medicine market grew 1.5× in three years" https://www.tsr-net.co.jp/data/detail/1201494_1527.html
- National Consumer Affairs Center, "Aesthetic medical services: complaint volumes and trends" https://www.kokusen.go.jp/soudan_topics/data/biyo.html
- MHLW, "Handling of aesthetic medicine" https://www.mhlw.go.jp/stf/newpage_65283.html
- MHLW, "Report of the review committee on appropriate provision of aesthetic medicine" (November 22, 2024) https://www.mhlw.go.jp/content/10801000/001341003.pdf
- Hifuko News, "Amended Medical Care Act phases in: monitoring and disclosure institutionalized" https://biyouhifuko.com/news/japan/15832/
- Hifuko News, "669 domestic facilities offered exosome therapy in 2023" https://biyouhifuko.com/news/japan/9673/
- Nikkei, "MHLW considers regulating exosome therapy" https://www.nikkei.com/article/DGXZQOUF019N70R00C26A7000000/
- M3 DigiKar, "What is the chokubi restriction?" https://digikar.m3.com/articles/opening/article79